![](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/66b3af25e86a5d84edad91cba7360f2160760590-3750x5000.jpg?fit=crop&auto=format)
FS-1502 Demonstrates Promising Antitumor Activity in HER2+ Breast Cancer
FS-1502, an anti-HER2 antibody drug conjugate (ADC) was well tolerated and demonstrated promising antitumor activity in patients with HER2-positive advanced breast cancer, according to a phase 1a/1b, open-label, single-arm study (NCT03944499) published …